In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database

Aims In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmacovigilance system. Methods An exhaustive case...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2022-03, Vol.88 (3), p.942-964
Main Authors: Saint‐Lary, Laura, Diallo, Alpha, Monteynard, Laure‐Amélie, Paul, Christelle, Marchand, Lucie, Tubiana, Roland, Warszawski, Josiane, Mandelbrot, Laurent, Rekacewicz, Claire, Petrov‐Sanchez, Ventzislava, Faye, Albert, Sibiude, Jeanne, Dabis, François, Sommet, Agnès, Leroy, Valériane
Format: Article
Language:English
Subjects:
adverse pregnancy outcomes
ANRS
antiretroviral drugs
HIV
Life Sciences
pharmacovigilance
Santé publique et épidémiologie
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims In 2018, 1.07 million pregnant women received antiretroviral drugs, raising whether this affects pregnancy outcomes. We assessed the adverse pregnancy outcomes associated with prenatal antiretroviral drug exposure, notified to the French ANRS pharmacovigilance system. Methods An exhaustive case report series has been performed using the ANRS pharmacovigilance database. All ANRS‐sponsored HIV clinical research studies using antiretroviral drugs either in pregnant women or women of childbearing age were eligible from 2004 to 2019. We analysed the following pregnancy outcomes: abortion, ectopic pregnancy, stillbirth, prematurity (
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15075